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The role for localized radiation to treat ovarian cancer (OC) patients with locally recurrent vaginal/perirectal
lesions remains unclear, though we hypothesize these patients may be salvaged locally and gain long-term
survival benefit. We describe our institutional outcomes using intensity modulated radiation therapy (IMRT)
+/- high-dose rate (HDR) brachytherapy to treat this population. Our primary objectives were to evaluate
complete response rates of targeted lesions after radiation and calculate our 5-year in-field control (IFC) rate.
Secondary objectives were to assess radiation-related toxicities, chemotherapy free-interval (CFI), as well as postradiation progression-free (PFS) and overall survival (OS). PFS and OS were defined from radiation start to either
progression or death/last follow-up, respectively. This was a heavily pre-treated cohort of 17 recurrent OC pa
tients with a median follow-up of 28.4 months (range 4.5–166.4) after radiation completion. 52.9% had highgrade serous histology and 4 (23.5%) had isolated vaginal/perirectal disease. Four (23.5%) patients had infield failures at 3.7, 11.2, 24.5, and 27.5 months after start of radiation, all treated with definitive dosing of
radiation therapy. Patients who were platinum-sensitive prior to radiation had similar median PFS (6.5 vs. 13.4
months, log-rank p = 0.75), but longer OS (71.1 vs 18.8 months, log-rank p = 0.05) than their platinum-resistant
counterparts. Excluding patients with low-grade histology or who were treated with palliative radiation, median
CFI was 14.2 months (range 4.7 – 33.0). Radiation was well tolerated with 2 (12.0%) experiencing grade 3/4
gastrointestinal/genitourinary toxicities. In conclusion, radiation to treat locally recurrent vaginal/perirectal
lesions in heavily pre-treated OC patients is safe and may effectively provide IFC.

1. Introduction
Despite recent advances in primary and maintenance therapies for
patients with ovarian carcinoma (OC), over 80% will recur and experi
ence treatment-related toxicities. The landscape of therapeutic options
in the recurrent setting is driven by platinum response, and most
commonly includes systemic therapies such as chemotherapy, biologic
targeted therapies, immunotherapy, and even endocrine therapy (NCCN
Guidelines, 2020). Prior to the development of effective palliative
chemotherapy options, pelvic radiation was used for local control (Firat
and Erickson, 2001). However, this modality fell out of favor because it

failed to address upper abdominal disease, while whole abdomen radi
ation produced toxicities that outweighed its limited benefits. Never
theless, while current guidelines reserve a role for localized radiation to
palliate symptoms, (NCCN Guidelines, 2020) it remains unclear who
benefits most from this localized treatment modality.
The small, but growing body of literature on radiation for recurrent
OC has documented responses in heterogeneous populations with oli
gometastatic disease (i.e. vaginal/rectal implants vs. localized nodal and
extranodal recurrences in the abdomen and/or pelvis) with limited
insight into which subgroups experience clinical benefit (Firat and
Erickson, 2001; Albuquerque et al., 2016; Chundury et al., 2016;
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Westhoff et al., 2016; Kim et al., 2019; Brown et al., 2013; Yahara et al.,
2013; Chang et al., 2018; Smart et al., 2019; Onal et al., 2020). Though
the reported incidence of oligometastatic vaginal/perirectal OC re
currences appears low, (Casey et al., 1996) these areas are unique in that
they may be salvaged with targeted radiation to improve not only local
control and long-term survival, but also to effectively palliate symptoms.
Thus, we aimed to better define the patient population with vaginal/
perirectal oligometastatic OC recurrences who benefits from radiation
and what toxicities may result from this treatment modality. Here, we
describe our institutional experience utilizing intensity modulated ra
diation therapy (IMRT) +/- high dose-rate (HDR) brachytherapy to treat
vaginal and perirectal recurrences in OC patients. Our primary objec
tives were to evaluate complete response rates of targeted lesions after
radiation and calculate the 5-year in-field local control (IFC) rate. Sec
ondary objectives were to assess radiation-related toxicities, as well as
post-radiation progression-free survival (PFS) and overall survival (OS).

platinum sensitive, but only 3 were platinum sensitive immediately
preceding radiation.
Table 2 summarizes treatment characteristics of patients stratified by
oligometastatic and multi-site recurrence. Overall, this was a heavily
pretreated population. Patients had received a median of 3 lines of
chemotherapy prior to radiation (range 1–9), including 3 who received
concurrent chemoradiation. Eleven of the 17 patients received definitive
radiation; median time for radiation completion was 41 days (range
11–105). One patient (ID 17) experienced extended time to completion
of a total of 105 elapsed days—45 days for initial photon treatment,
6000 cGy in 30 fractions, followed by proton boost, 30 cobalt gray
equivalents (CGE) in 15 fractions. This plan was specifically individu
alized for this patient, as she was the only one in our series who received
proton therapy. The two patients with the longest CFI after radiation
included a BRCA2 mutation carrier (ID 11) with isolated disease to the
vagina, while the other (ID 14) had a mismatch repair deficient (MLH1)
tumor treated with concurrent radiation and pembrolizumab.
Median follow-up after radiation was 28.4 months (range
4.5–166.4). Fifteen (88.2%) patients achieved a complete response of
targetable lesion(s) after radiation. Four (23.5%) patients (ID 8, 6, 11
and 10) had in-field failures at 3.7, 11.2, 24.5, and 27.5 months after
start of radiation (Fig. 1). Two were BRCA carriers, and 3 received
additional radiation to the vaginal cuff/perirectal area. A detailed
narrative of these 4 patients and their management strategies are pro
vided in Supplemental Table 1. Eleven women were treated with cura
tive intent, and among them, 7 (64%) were free of disease within the
treatment field at last follow-up. Ten patients were evaluable for 5-year
follow-up after radiation, contributing to a 5-year IFC rate of 70%.
At the time of this analysis, 3 (17.6%) patients were alive with no
evidence of disease, 2 (11.8%) were alive with disease, and 12 (58.8%)
were dead of disease. Overall median PFS post-radiation was 11.0
months (range 2.6–27.5). Patients treated with definitive intent (n =
11), had a 13.4 month longer median PFS than those treated with
palliative doses (18.6 vs 5.2 months, p = 0.01). PFS did not differ when
stratified by platinum status prior to radiation. The 9 patients who were
platinum-sensitive prior to radiation had similar median PFS (6.5 vs.
13.4 months, log-rank p = 0.75), but longer OS (71.1 vs 18.8 months,
log-rank p = 0.05, Fig. 2) compared to their platinum-resistant coun
terparts. Excluding patients with low-grade serous histology and those
who were treated with palliative intent, the median CFI was 14.2
months (range 4.70–33.0) with no impact on PFS or OS when stratified
by CFI < 12 months vs. ≥ 12 months.
Overall radiation was well tolerated with 2 patients experiencing
grade 3/4 toxicities. Patient 12 had a vesicovaginal fistula repair 5
months prior to radiation and the fistula recurred during her last week of
radiation for multisite disease (vaginal cuff and retroperitoneal aden
opathy). Patient 5 was diagnosed with a parastomal hernia and bowel
perforation outside of the radiated field approximately 4 weeks after
completing palliative pelvic IMRT + HDR brachytherapy for multi-site
disease. This was thought to be due to a 10 cm mass eroding into the
colon and she eventually succumbed from this event.

2. Methods
This case series included 17 patients with recurrent OC who received
IMRT, HDR brachytherapy, or both for vaginal and/or perirectal re
currences at Washington University School of Medicine from January
2006 to November 2019. Eligible patients were identified from our
Radiation Oncology institutional database. Initial treatment planning,
simulation, treatment devices, and radiation treatment plans were
individualized at the discretion of the treating radiation oncologist. This
retrospective review was approved by the Washington University
Institutional Review Board (#202005019).
We included patients with recurrent OC, regardless of stage or his
tology, with a vaginal and/or perirectal recurrence as determined by
computed tomography (CT), 18-fluoro-deoxyglucose positron emission
tomography (FDG-PET), and/or magnetic resonance imaging (MRI).
Patients were subdivided by oligometastatic, defined as 1–5 metastatic
lesions, (Lievens et al., 2020) or multi-site recurrence prior to radiation.
Following radiation, patients were seen for 6-week post-radiation
exams by either a radiation oncologist or gynecologic oncologist, and
thereafter according to systemic treatment schedules, but at least every
3 months. Radiation related toxicities were categorized as acute (≤28
days) or late (>28 days) and graded per common terminology criteria
for adverse events (CTCAE) version 5.0 (Cancer Therapy Evaluation
Program (CTEP), 2017). All patients were followed until death or time of
analysis.
OS was defined from start of radiation to death or last follow-up at
time of analysis. PFS was defined from start of radiation to progression
(evidenced by imaging or initiation systemic therapy), death, or last
follow-up at time of analysis. IFC was defined as no recurrence within
the radiated field as determined by PET/CT, CT, MRI, or clinical exam.
Those suspected of recurrence following radiation did not require biopsy
for histologic confirmation. Chemotherapy-free interval (CFI) was
calculated as the time between radiation start and next line of chemo
therapy. OS, PFS, and IFC were calculated using Kaplan-Meier method.
The log rank test was used to compare PFS and OS after radiation
stratified by pre-radiation platinum status. All tests were two-sided with
a significance level of 0.05. SAS Version 9.4 (Cary, NC) was used to
perform all statistical analyses.

4. Discussion
Focused radiation therapy led to durable IFC for most OC patients
with recurrence involving the vaginal apex and/or perirectal area. As
expected, genitourinary and gastrointestinal side effects were most
frequent, but grade 3–4 complications were uncommon. However, OS
was determined by platinum sensitivity, suggesting that subsequent
chemotherapy plays a role in determining survival. Our results support
continuing our ongoing institutional practice to evaluate patients with
limited metastatic burden for targeted radiation with the goal of
providing treatment breaks from systemic therapy, palliation of symp
toms, and effective locoregional control.
Prior studies exploring localized radiotherapy, including our own
institutional data from 2016, historically included heterogeneous

3. Results
A total of 17 patients were included in the analysis, 4 with oligo
metastatic disease and 13 with multi-site disease. Table 1 summarizes
patient clinical characteristics. All but 2 patients were white, the median
age at diagnosis was 58 (range 38–77), and most had stage III disease
and high-grade serous histology. Of the 12 patients with available ge
netic testing results, 2 had germline mutations in BRCA2, 1 in BRCA1,
and 1 in MLH1. All 4 (23.5%) patients (ID 10, 11, 16, and 17) with
oligometastatic disease confined to the vagina/rectum were initially
2
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Table 1
Summary of clinical characteristics.
ID

Age at RT
(years)

N = 66
17 (39–81)

Race

White
(15)

Histology

Stage Genetics

Optimally Debulked Location Treated with RT Time to RT
(<1cm)
from Dx
(months)

Initial Platinum
Status

Pre-RT Platinum
Status

HG Serous (9)
LG Serous (2)
Clear Cell (2)
Mixed (3)
Carcinosarcoma (1)

I (3) BRCA (3)
II (2) MLH1 (1)
III (9)
IV
(3)

Yes (8)

Vaginal apex (17)

75
(9–149)

Sensitive (14)
Resistant (2)
Refractory (1)

Sensitive (8)
Resistant (7)
Refractory (1)
Unknown (1)

Vaginal apex, Left paraaortic LN
Vaginal apex, Right
external iliac LN
Vaginal apex, three
abdominal & pelvic
masses, RP LN
Vaginal apex,
Peritoneum, Serosa, Left
inguinal, Mediastinum
Vaginal apex (involving
bladder & sigmoid
colon), Left iliac LN
Mesenteric implants
Vaginal apex, Left
external iliac LN
Vaginal apex, hilum,
Inguinal LN
Vaginal apex, Pelvis

53

Sensitive

Resistant

73

Sensitive

Sensitive

18

Sensitive

Sensitive

149

Sensitive

Sensitive

74

Sensitive

Resistant

148

Sensitive

Sensitive

36

Resistant

Resistant

135

Sensitive

Resistant

Vaginal apex, L SVC,
113
Lung,
Left abdominal wall, LNs:
Left PA, Right inguinal,
Right external iliac
Vaginal apex
35
Vaginal apex
81

Sensitive

Sensitive

Sensitive
Sensitive

Sensitive
Sensitive

Vaginal apex, RP
adenopathy
Vaginal fornix, Spleen,
Liver,
Left iliac, Peritoneum,
Left rectus
Vaginal apex, LNs: RP,
Left iliac
Vaginal apex, bladder
dome,
Left iliac
Perirectal & Vaginal apex
Vaginal apex

9

Refractory

Refractory

78

Sensitive

Sensitive

10

Resistant

Resistant

75

Sensitive

Resistant

87
139

Sensitive
Sensitive

Sensitive
Resistant

1

81

White

HG Serous

IIIb

Unknown

No

2

61

White

HG Serous

IIIc

Unknown

No

3

78

Asian

Clear cell

Ic

Negative*

No

4

49

White

LG Serous

IVb

Unknown

No

5

66

White

HG Serous

IIIc

Unknown

No

6

79

White

HG Serous

IIc

BRCA1

No

7

80

White

HG Serous

IVb

Unknown

No

8

75

White

LG Serous

IIIc

Yes

9

67

White

HG Serous

IIIc

Negative
BRCA1/2
Negative
BRCA1/2

10
11

79
53

White
White

Negative*
BRCA2

Yes
Yes

12

59

White

HG Serous
IIIc
Gr 3 Endometrioid and HG Ib
Serous
Carcinosarcoma
IVa

Negative*

No

13

57

Black

HG Serous

IIIc

BRCA2

Yes

14

39

White

Clear cell

Ic

MLH1

Yes

15

56

White

Carcinosarcoma
(HG Serous)

IIIc

Negative*

Yes

16
17

74
65

White
White

HG Serous
IIIc
Gr 3 Endometrioid and HG IIIc
Serous

Negative*
RAD51C
VUS

Yes
Yes

No

RT: radiation; Dx: diagnosis; HG: high-grade, Gr: grade; LG: low-grade; LN: lymph node; RP: retroperitoneal.
*
Patients were screened with a multi-gene panel.

populations of OC patients, many with localized nodal and extranodal
recurrences in the abdomen and/or pelvis (Albuquerque et al., 2016;
Chundury et al., 2016; Westhoff et al., 2016; Kim et al., 2019; Brown et al.,
2013; Yahara et al., 2013; Chang et al., 2018; Smart et al., 2019; Onal
et al., 2020). Nevertheless, rates of local control at 2 and 3 years after
radiation are > 80% and 5-year IFC rates as high as 71% (Albuquerque
et al., 2016; Brown et al., 2013). More recently, the SABR-COMET trial
reported a 5-year OS benefit among patients with metastatic solid tumors
treated with palliative radiation vs ablative therapy (17.7% vs. 42.3%
,95% CI, 28–56%; p = 0.006), with no new grade 2–5 adverse events or
differences in quality of life (Palma et al., 2020). Though this study
excluded gynecologic oncology patients, our study results show compa
rable rates of 5-year in-field control (70%) when targeted local radiation
therapy is employed in this patient population. Importantly, due to the

anatomic location of tumors in this study, patients experiencing in-field
recurrence were frequently salvaged with additional radiation. Of the
17 patients in our case series, four had undergone a diverting ostomy prior
to initiation of radiation, either as a part of their upfront staging surgery
(n = 1) or during a secondary cytoreductive surgery (n = 3). Nevertheless,
no patients underwent a diverting procedure after radiation completion.
Collectively, this data suggests that in carefully selected women with
recurrent OC localized to the pelvis and involving the vagina and/or
perirectal area, there may be a potential advantage to delivering
aggressive local radiation. This can be administered with limited toxicity,
and provide heavily pretreated patients treatment breaks from systemic
therapy. Furthermore, we show a median CFI post-radiation of 14.2
months, which for platinum-resistant patients, could lead to re-challenge
with a platinum or additional agents.
3
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Table 2
Treatment and outcomes.
ID

Lines of
chemo prior
to RT
(n)

RT modality

Oligometastatic disease
10
2
HDR Brachytherapy
(Vaginal cylinder),
IMRT
11
2
IMRT
16
17

3
3

IMRT
IMRT

Multisite disease: IMRT + HDR Brachytherapy
5
8
HDR Brachytherapy
(Vaginal cylinder),
IMRT
12
1
HDR Brachytherapy
(Vaginal cylinder),
IMRT
15
3
HDR Interstitial
brachytherapy, IMRT
Multisite disease: IMRT alone
1
4
IMRT
8
4
IMRT#
2
1
IMRT
3
1
IMRT

Intent of
RT

RT alone

Total RT
dosage
(cGy)

Dose/
Fraction
(cGy)

In field
failure

Grade 3/4
toxicities

Survival after
RT (months)

Status

Definitive

Yes

1000, 6000

500, 200

Yes

No

52.6

Alive with
disease

Definitive

Yes

6000

200

Yes

No

38.2

Definitive
Definitive

Yes
Yes

5940
6000

180
200

No
No

No
No

16.6
7.6

Alive
without
disease
Dead
Alive with
disease

Palliative

Yes

1000, 5040

500, 180

No

Yes

4.5

Dead

Definitive

Yes

1000, 6000

500, 200

No

Yes

14.0

Dead

Definitive

Yes

1800, 5940

225, 180

No

No

16.5

Dead

Definitive
Definitive
Definitive
Palliative

5040
5040
6000
5040

180
180
200
180

No
Yes
No
No

No
No
No
No

38.0
58.8
69.8
89.1

5000
6000
6000

200
200
200

No
No
No

No
No
No

28.5
28.7
26.0

Dead
Dead
Dead
Alive
without
disease
Dead
Dead
Dead

4
5
IMRT
9
9
IMRT
13
8
IMRT
Multisite disease: HDR Brachytherapy alone
6
1
HDR Brachytherapy
(Vaginal cylinder)#
7
2
HDR Brachytherapy
(Vaginal cylinder)

Palliative
Palliative
Palliative

Yes
Yes*
Yes
No, concurrent
carboplatin &
paclitaxel
Yes
Yes
Yes

Definitive

Unknown^

2400

400

Yes

No

166.4

Dead

Palliative

4800

800

No

No

4.7

Dead

14

Definitive

No, concurrent
bevacizumab/
pemetrexed
No, concurrent
pembrolizumab

4800

800

No

No

20.6

Alive
without
disease

1

HDR Brachytherapy
(Vaginal cylinder)

Fig. 1. Kaplan-Meier estimates of IFC, PFS, and OS among recurrent ovarian cancer patients treated with radiation.
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Log-rank p=0.045

Pre-Radiation Platinum Sensitive

Pre-Radiation Platinum Resistant

Fig. 2. Kaplan-Meier analysis showing OS after radiation stratified by pre-radiation platinum status.

locoregional pelvic recurrence as it may lead to improved clinical
outcomes.
Author Contributions

Our case series has several limitations impacting interpretation of
data and extrapolation to the recurrent OC patient population at large.
Given the small sample size and high rates of complete response to ra
diation, we were unable to perform subgroup analyses to better under
stand predictors of complete response to radiation and 5-year IFC.
Though platinum status prior to radiation was collected, subgroup
analysis was not feasible to further explore the impact of platinumsensitivity to radiation response and IFC. Our small sample size also
did not allow for meaningful comparisons between different radiation
modalities (IMRT versus brachytherapy), dose, and volumes for optimal
tumor response, nor could we stratify by important clinical character
istics such as tumor number, size, or location (vaginal apex/perirectal
area vs other), histology, number of therapies prior to radiation, and
genetic status. Additionally, although radiation was generally well
tolerated, we do not have quality of life data for this cohort to determine
symptomatic benefit from radiation.
Future studies should examine utilization of other modalities to
deliver aggressive local radiation to locally recurrent OC patients as
employed in this study. Our institution is actively examining stereotactic
radiation utilizing MRI-guidance and adaptive treatment planning to
test whether this approach can provide patients with shortened treat
ment times (days instead of weeks) while maintaining desired clinical
outcomes for treatment sites throughout the body without increasing
adverse events. Additionally, the timing of radiation in relation to
chemotherapy should be investigated. At present, there is no consensus
regarding initiation of radiation in patients with locoregional recur
rence. In our study, time from diagnosis to first round of radiation
therapy was > 5 years. Potentially, initiation of local therapy earlier in
the treatment course could provide greater therapeutic benefit, while
simultaneously reducing cumulative treatment-related toxicity and
improving quality of life outcomes. Finally, it will be important to
identify any clinical (platinum sensitivity, histology, etc.) or genetic
markers (tumor mutational burden, BRCA status) within the population
that may predispose patients to greater benefit from aggressive local
therapy.
In conclusion, our data suggests that utilization of aggressive local
therapy with radiation for patients with locoregional pelvic recurrence
is safe, provides effective IFC, leading to increased CFI, with minimal
gastrointestinal/genitourinary side effects. We propose that radiation
should be considered for appropriately selected patients at the time of
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